

201-142

4-12-65

1/1

36

Printed in U.S.A.

icide

INGREDIENTS
Dihydro-2,2,4-trimethyl-2H-pyridin-3(1H)-one
100.0%

BY WEIGHT
82.0%
18.0%
TOTAL
100.0%

PRECAUTIONS IN USING
From children and domestic animals.
Do not allow to drift to areas occupied by unprotected humans or domestic animals.
Do not use on humans and animals should be kept out of treated fields on the patient.

CONTAMINATE AND DESTROY USED CONTAINERS
These containers should be washed thoroughly with a strong solution of alkali detergent and rinsed with water.
Containers by breaking, crushing, deep-freezing, then bury.

NOTE TO PHYSICIAN
ADVERSE SYMPTOMS: Symptoms include weakness, headache, dizziness, blurred vision, non-reactive pupils, salivation, sweating, vomiting, diarrhea and abnormal cramps and/or convulsions.
If the patient is in the specific therapeutic range of chloroquine, the patient should be given a specific antidote.
If the patient is in the specific therapeutic range of chloroquine, the patient should be given a specific antidote.
If 1 to 2 G. is given, until complete absorption has occurred, it is an in-ter-est treatment. Clear chest by postural drainage. Oxygen administration may be necessary. Observe patient continuously for 48 hours. Exposure to cholinesterase inhibitors may without warning cause a fatal attack. In very small doses of any cholinesterase inhibitor, the further exposure until time for cholinesterase regeneration has been determined by blood test.

its use, storage or handling.

D. S. Patent No. 2,802,855
AC 3020